Hacker News Reader

I argue many Type 2 patients do a VERY POOR job on average on monitoring their diabetes. Many Type 2 still have moderately functioning cells that manufacture insulin...Type 1 have no choice.

I argue the opposite in that Nightscout and other initiatives that predominately serve the Type 1 community help push the advancement of monitoring, etc. that benefit the rest.

View on HN

Nightscout is a great initiative. Monitoring of type 2 is rapidly improving, especially as CGMs aren’t restricted to type 1s on insurance as much as they sued to be. Increasing the market size of CGMs has led to significant competition.

Thought on treating type 2 is also evolving in ways that don’t benefit type 1 as much. For example, the trend is for pre-diabetes to be taken seriously and detected earlier.

Reply on news.ycombinator.com